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GDE1 is a mammalian glycerophosphodiesterase
(GDE) implicated by in vitro studies in the regulation
of glycerophophoinositol (GroPIns) and possibly
other glycerophospho (GroP) metabolites. Here, we
show using untargeted metabolomics that GroPIns
is profoundly (>20-fold) elevated in brain tissue
from GDE1(/) mice. Furthermore, two additional
GroP metabolites not previously identified in eukary-
otic cells, glycerophosphoserine (GroPSer) and
glycerophosphoglycerate (GroPGate), were also
highly elevated in GDE1(/) brains. Enzyme assays
with synthetic GroP metabolites confirmed that
GroPSer and GroPGate are direct substrates of
GDE1. Interestingly, our metabolomic profiles also
revealed that serine (both L-and D-) levels were
significantly reduced in brains of GDE1(/) mice.
These findings designate GroPSer as a previously
unappreciated reservoir for free serine in the nervous
system and suggest that GDE1, through recycling
serine from GroPSer, may impact D-serine-depen-
dent neural signaling processes in vivo.
INTRODUCTION
The glycerophosphodiester phosphodiesterases (GDEs) are an
ancient and ubiquitous family of enzymes with numerous
members found in all three domains of life. These enzymes are
metal-dependent phosphodiesterases that cleave the phospho-
diester bond of various glycerophosphodiester (GroP) metabo-
lites, such as the deacylated phospholipids glycerophospho
choline (GroPCho) and glycerophosphoinositol (GroPIns), to
release glycerol-3-phosphate (G3P) and the corresponding
head-group alcohol. Several prokaryotic GDEs have been
characterized and shown to be necessary for catabolism of envi-
ronmental GroP metabolites, suggesting a role for these
enzymes in phospholipid remodeling and nutrient scavengingChemistry & Biology 17, 83(Larson et al., 1983; Tommassen et al., 1991). Transporters for
GroP metabolites have also been identified in microbes and
mammals, indicating that dedicated systems exist for GroP-
metabolite uptake and catabolism (Fisher et al., 2005; Mariggio
et al., 2006; Patton-Vogt and Henry, 1998).
Following the characterization of microbial GDEs, a group of
mammalian GDEs was identified that contains seven members
(GDE1-7) with diverse patterns of expression (Yanaka, 2007).
In contrast to microbial GDEs, which are predominantly periplas-
mic or cytoplasmic, six of the seven mammalian GDEs are
membrane bound and possess multiple membrane-spanning
domains, suggesting that their functions may have diverged
significantly from their prokaryotic ancestors. The physiological
roles ascribed to mammalian GDEs are diverse. GDE2 has
been shown to regulate motor neuron differentiation by a mech-
anism that depends on the integrity of its catalytic residues (Rao
and Sockanathan, 2005; Yan et al., 2009), and a separate report
implicated GDE2 in the regulation of GroPCho levels in the
kidney (Gallazzini et al., 2008). GDE3 has been found to promote
osteoblast differentiation upon transient overexpression (Yanaka
et al., 2003). Recently, GroPIns was identified as a substrate for
GDE3, and, interestingly, GDE3 displays phospholipase C-type
activity (releasing inositol-phosphate and glycerol) rather than
the D-type phospholipase activity exhibited by other character-
ized GDEs (Corda et al., 2009a). Finally, GDE1 has been shown
to interact with regulators of G protein signaling (Zheng et al.,
2000), and its catalytic activity can be modulated by stimulation
of G protein-coupled receptors (Zheng et al., 2003). GroPIns is
a substrate for GDE1 in vitro (phospholipase D-type hydrolysis),
and several other GroP metabolites, including GroP-serine
(GroPSer) and GroP-inositol-4,5-bisphosphate, can competi-
tively inhibit the action of GDE1 on GroPIns (Zheng et al.,
2003), suggesting that these GroP compounds might also be
direct GDE1 substrates. Finally, we discovered that GDE1, but
not other mammalian GDEs, also accepts GroP-N-acyl ethanol-
amines (GP-NAEs) as substrates, implicating this enzyme in the
biosynthesis of NAE transmitters, such as the endocannabinoid
anandamide (Simon and Cravatt, 2008). Consistent with this
premise, we have found that mice harboring a targeted disrup-
tion of the GDE1 gene display a moderate impairment in acute
NAE biosynthesis (Simon andCravatt, 2010). The extent towhich1–840, August 27, 2010 ª2010 Elsevier Ltd All rights reserved 831
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Novel Substrates for GDE1 Revealed by Metabolomicsother GroPmetabolites are altered in GDE1(/) mice, however,
has not yet been examined.
Here, we present a global analysis of GDE1(/) mice using
a mass spectrometry (MS)-based metabolomics platform that
measures aqueous-soluble, polar analytes, including GroP
metabolites and their derivatives. We confirmed that GroPIns is
a physiological substrate of GDE1 that is profoundly elevated
in the central nervous system of mice lacking this enzyme. Addi-
tionally, we discovered other GDE1-regulated metabolites,
including GroPSer and GroPGate, that, to our knowledge, have
not yet been described as natural products in eukaryotes.
Finally, our broad metabolomic profiles also revealed lower
serine levels in brains of GDE1(/) mice, suggesting that
GroPSer serves as a previously unappreciated reservoir for
free serine in the nervous system.
RESULTS
Analysis of GDE1(–/–) Mice by Untargeted
Metabolomics
The ability to measure and study GroPIns and its derivatives has
been facilitated by the availability of 3H-inositol, which can be
used to metabolically label cultured cells to track the fate of
inositol-containingmetabolites (Emilsson and Sundler, 1984; Fa-
lasca et al., 1996, 1997). While this technique is powerful, it is not
readily applicable to organismal studies, and is dependent on the
availability and facile metabolic incorporation of radioactive
standards. Consequently, comparatively little is known about
GroPInsmetabolism in vivo or the existence and enzymatic regu-
lation of other GroP metabolites due to a dearth of synthetic and
analytical chemistry techniques for their characterization and
measurement. MS-based metabolomics has emerged as
a powerful strategy to globally investigate biochemical pathways
in living systems and has succeeded in assigning novel
substrates and products to both characterized and uncharacter-
ized enzymes (Chiang et al., 2006; Dang et al., 2009; Saghatelian
et al., 2004; Tagore et al., 2009; Tang et al., 2009; Vinayavekhin
and Saghatelian, 2009). Such MS-based metabolomics experi-
ments can be performed in two different ways: targeted or untar-
geted. Targeted analyses focus on a defined set of known
metabolites that are typically measured by selected-ion moni-
toring or multiple-reaction monitoring with internal standards
for absolute or relative quantitation (Jackson et al., 2008;
McNally et al., 2006, 2007; Rabinowitz and Kimball, 2007). In
contrast, untargeted metabolomics surveys a broad mass range
for relative changes in both known and unknown metabolites.
Untargeted profiling involves a comparative liquid chromatog-
raphy (LC)-MS analysis of two sets of samples, e.g., cells/tissues
from wild-type and enzyme-disrupted systems, to identify
differences in the intensity of mass ion peaks that share mass-
to-charge ratios and retention times.We and others have applied
untargeted metabolomics to analyze organically extracted
fractions of cells and tissues, which provide preferential access
to hydrophobic, non-polar metabolites (a process often referred
to as ‘‘lipidomics’’) (Garrett et al., 2009; Guan et al., 2007;
Ivanova et al., 2009; Saghatelian et al., 2004). However, many
of the putative substrates for GDE1 are hydrophilic, polar metab-
olites that would likely remain in the aqueous fractions of cell/
tissue extracts and thus go unsampled in conventional lipidomic832 Chemistry & Biology 17, 831–840, August 27, 2010 ª2010 Elseviexperiments. We therefore set out to establish a method to
analyze the aqueous-soluble metabolome that combines normal
phase LC-MS conditions as pioneered by Rabinowitz and
co-workers for their targeted metabolomic studies (Bajad
et al., 2006) with an untargeted profiling protocol suitable for
the discovery of both known and novel metabolites (Saghatelian
et al., 2004).
We identified optimal extraction and chromatography
methods by testing a diverse collection of aqueous-soluble
metabolites, including nucleosides, amino acids, and synthetic
GroP metabolites under normal phase chromatography condi-
tions (see Table S1 available online). GroP metabolites were ob-
tained from their respective phospholipids by alkaline hydrolysis
and subsequent purification (see Experimental Procedures). We
next applied our optimized extraction and LC-MS conditions to
perform an untargeted comparative analysis of water-soluble
metabolites from brain tissue of GDE1(+/+) and (/) mice. Initial
full-scan LC-MS surveys in negative mode analyzed an m/z
range from 100 to 1200, and the XCMS software (Benton et al.,
2008; Smith et al., 2006) was used for comparative data analysis.
Three metabolites with different m/z values (258.0, 259.0, and
333.0) and LC retention times (24.4, 27.0, and 23.9 min, respec-
tively) were found to be dramatically elevated (>20-fold) in GDE1
(/) brains (Figures 1A and 1B). Metabolomes from spinal cord
showed similar overall profiles to brain (Table S2).
Structural Characterization of GDE1-Regulated Brain
Metabolites
Previous studies by the Farquhar group showed that GDE1 is
a GroPIns phosphodiesterase in vitro (Zheng et al., 2003). As
such, we presumed that them/z 333.0metabolite was likely Gro-
PIns, a premise supported by high-resolution mass spectrom-
etry (HRMS) measurements, which assigned an exact mass
value within 0.1 ppm of the expected value for GroPIns (Table
S3). Chemical synthesis of GroPIns and comparison of its LC
retention-time and MS/MS fragmentation pattern to the natural
GDE1-regulated metabolite confirmed its identity as GroPIns
(Figures 2A and 2B; Figure S1A).
In the aforementioned Farquhar study (Zheng et al., 2003),
competition experiments revealed that several GroPmetabolites,
including GroPSer, could inhibit GroPIns hydrolysis by GDE1.
These data suggested that GroPSer might also serve as a GDE1
substrate, although, to our knowledge, GroPSer had not previ-
ously been identified as a natural metabolite in eukaryotes. The
monoisotopic mass of the GroPSer anion ([M-H]-) is 258.04,
providing a candidate identity for the m/z 258.0 metabolite that
was dramatically elevated in GDE1(/) brains. Preparation of
GroPSer via alkaline hydrolysis of phosphatidylserine (PtdS)
yielded a molecule with an identical LC-elution profile, high-reso-
lution mass (within 0.3 ppm), and MS/MS fragmentation pattern
as the natural m/z 258 metabolite, thus confirming its identity as
GroPSer (Figures 2C and 2D; Figure S1B and Table S3).
Structural assignment of them/z 259 metabolite proved more
challenging, as this mass did not match those of any known or
predicted GDE1 substrates. We obtained HRMS data for this
metabolite and found that the anion ([M-H]-) had an exact
mass of 259.022, which suggested a molecular formula of
C6H13NO8P
-. Searches of publicly available metabolite
databases revealed that this is the chemical formula forer Ltd All rights reserved
Figure 1. GDE1(/) Brains Contain Markedly Elevated Levels of Multiple Metabolites
(A) Mass ion peak intensity measurements from GDE1(+/+) versus (/) brains. Data are derived from untargeted metabolite profiling experiments performed in
the negative ionization mode. Red spots represent m/z ions that are significantly elevated in GDE1(/) brains (in each case, fold-change >10) and their m/z
values are displayed. Isotopologs, adducts, and ions produced by in-source fragmentation were manually removed for clarity.
(B) Extracted ion chromatograms (EICs) from individual LC-MS runs of GDE1(+/+) and (/) brain metabolomes. The retention times for the relevant peaks are
shown in minutes.
See also Figure S1 and Tables S1 and S4.
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phate as an initial candidate structure. However, fragmentation
studies performed on the endogenous m/z 259 metabolite re-
vealed fragment ions with m/z values of 152.993 and 171.004,
which are characteristic of a glycerol-phosphate backbone (Fig-
ure 2F), and, indeed, comparison with synthetic inositol-mono-
phosphate standards revealed that these species did not co-
elute with the m/z 259 metabolite (Figure S1D). Working with
the knowledge that them/z 259metabolite likely contains a glyc-
erol-phosphate backbone, we surmised that the alcohol head-
group could represent glyceric acid (glycerate), which would
engender a small-molecule glycerophosphoglycerate (GroP-
Gate) with an exact mass value that matches the natural metab-
olite within 0.2 ppm (Table S3).
Key to the ultimate structural assignment was the chemical
synthesis of GroPGate as described in Experimental Proce-
dures. In brief, starting from GroPSer, the a-amino group of
serine was converted into an alcohol by diazotation in the pres-
ence of sodium nitrite to afford the carboxylic acid after hydro-
lysis (Lencina et al., 2008). The fragmentation of the synthetic
GroPGate standard revealed an m/z 166.970 ion corresponding
to the exact mass of the dehydrated phosphate adduct of the
glycerate head-group (Figure 2F). An identical fragmentation
pattern was obtained for the endogenous m/z 258 brain metab-
olite. Additionally the synthetic and natural species displayed
identical LC-elution profiles (Figure 2E; Figure S1C). Together,Chemistry & Biology 17, 83these data indicate that GroPGate is a novel natural product of
the mouse brain and a principal endogenous substrate for
GDE1. It should be noted, however, that we cannot formally
exclude the possibility that the m/z 259 metabolite represents
GroPGate conjugated via the 20 rather than 30 position on the
glycerate head-group, as it is not clear whether these two GroP-
Gate variants would show different retention times under our
chromatographic conditions. We suggest based on potential
biosynthetic pathways (see Discussion) that the 30-conjugated
GroPGate is a more likely structure.
Finally, it is important to note that not all detectable GroP
metabolites were elevated in GDE1(/) mice. Peaks corre-
sponding to GroP-ethanolamine (GroPEtn) and GroP-choline
(GroPCho) were identified in our metabolomic data by compar-
ison to synthetic standards (Figure S2 and Table S3) and
displayed similar levels in GDE1(+/+) and (/) brains (Table 1).
These findings indicate that GroPEtn and GroPCho are not
endogenous substrates for GDE1, which is consistent with
a previous study showing that neither GroPEtn nor GroPCho
competitively inhibits GDE1 activity in vitro (Zheng et al., 2003).
Evaluation of GroP Metabolites as GDE1 substrates
We next asked whether GroPSer and GroPGate, like GroPIns,
are direct substrates for GDE1. In support of this premise, the
membrane proteome from GDE1-transfected cells showed
significantly greater hydrolytic activity toward all three GroP1–840, August 27, 2010 ª2010 Elsevier Ltd All rights reserved 833
Figure 2. Structural Characterization of GDE1-Regulated Brain Metabolites
(A, C, and E) Chromatographic behavior on normal-phase LC of synthetic GroPIns, GroPSer, and GroPGate compared to the natural metabolites elevated in
brains of GDE1(/) mice. Insets show observed and calculated masses (o.m. and c.m., respectively) for natural metabolites, as measured by quadrupole
time-of-flight (QTOF) mass spectrometry (for higher resolution FT-ICR mass-measurements, see Table S4).
(B, D, and F) MS/MS spectra showing daughter ions that correspond to the glycerophosphate backbone (m/z 78.95, 96.97, 152.99, 171.00). Endogenous
daughter ions matched their synthetic counterparts within 20 ppm which is typical for MS/MS ions obtained via QTOF mass spectrometry.
The existence of the inositol (B) and glycerate (C) head-groups was confirmed by diagnostic peaks representing inositol- and dehydrated glycerate-phosphate,
respectively. MS/MS profiles of synthetic (blue) and natural (red) metabolites are shown. See also Figures S1 and S2 and Tables S2 and S3.
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transfected control cells (Figures 3A and 3B). Substrate assays
were also performed with brain membrane proteomes from
GDE1(+/+) and (/) mice, and much greater activity was
observed in GDE1(+/+) samples for all three GroP-substrates
(Figures 3C and 3D). GDE1 (either recombinant or natural) was
found to hydrolyze GroP metabolites with relative efficiencies
of GroPSer > GroPGate > GroPIns. Together, these studies indi-834 Chemistry & Biology 17, 831–840, August 27, 2010 ª2010 Elsevicate that GroPSer and GroPGate, like GroPIns, are direct
substrates for GDE1.
Serine Levels Are Reduced in Brain Tissue
from GDE1(–/–) Mice
Our metabolomic profiles had the potential to reveal additional
biochemical changes beyond the dramatic elevations in GroP
metabolites caused by GDE1 disruption. A survey of knowner Ltd All rights reserved
Table 1. Endogenous Levels of GroP Metabolites and Serine
in nmol/g Wet Brain Tissue as Measured by LC-MS
Metabolite
GDE1(/)
Brain
GDE1(+/+)
Brain
Ratio
(/)/(+/+) p value
GroPIns 647 ± 14 26.5 ± 0.1 25 0.02
GroPSer 933 ± 67 8.3 ± 0.2 112 0.03
GroPGate 1426 ± 10 %5a R285a 0.01
GroPEtn 3415 ± 360 3919 ± 381 0.87
GroPCho 10306 ± 1605 10240 ± 1182 1.01
Serine 990 ± 22 1626 ± 101 0.61 0.03
Data represent the average value of six independent experiments per
group ±SE.
aGroPGate signals from GDE1(+/+) tissue were below the detection limit
and are listed as%5 nmol/g tissue leading to a minimal (/)/(+/+) ratio
ofR285.
Chemistry & Biology
Novel Substrates for GDE1 Revealed by Metabolomicspolar metabolites, including amino acids and nucleosides,
revealed that most were unaltered in GDE1(/) brains
(Table S4). A 1.6-fold reduction was, however, observed for
the amino acid serine in GDE1(/) brains. Subsequent tar-
geted analysis using selected ion monitoring and a deuterated
(d3)-serine standard confirmed the significance of this 1.6-fold
decrease in serine in GDE1(/) brains (Figure 4A). Further-
more, the addition of d3-serine as an internal standard
permitted precise quantitation of absolute serine concentra-Figure 3. GroPSer, GroPIns, and GroPGate Are Direct Substrates of G
Membrane preparations from GDE1-transfected COS-7 cells (A and B) or mouse
olites with different head-groups : serine (GroPSer), glycerate (GroPGate), or inosit
free head group (serine, glycerate, and inositol from GroPSer, GroPGate, and Gr
samples, enzymeactivity againstGroPSer andGroPGatewasmeasured in the sam
substrate (due to the presence of high background isobaric mass signals for inosi
Student’s t test. (B) and (D) show western blots using an anti-Myc antibody (B) or
Chemistry & Biology 17, 83tions, which were found to be approximately 1.6 mmol/g brain
tissue in GDE1(+/+) mice, consistent with previous measure-
ments (Klivenyi et al., 2005; Nagata et al., 1994). To evaluate
the possibility that GroPSer serves as a metabolic precursor
to serine in the brain, we compared the magnitude of the
GroPSer elevation with the reduction in serine observed in
GDE1(/) mice. The synthesis of isotopically labeled GroP
metabolites was impractical so we compared the ionization of
endogenous GroP metabolites to standard curves generated
with synthetic, unlabeled GroPs (using d3-serine as a normal-
izing internal standard) to give estimates of endogenous GroP
levels in GDE1(+/+) and (/) brains. We found that the abso-
lute levels of GroPSer, GroPGate, and GroPIns were 933, 1426,
and 647 nmol/g in GDE1(/) brain and 8, %5, and 26 nmol/g
in GDE1(+/+) brain (Table 1). Thus, in GDE1(/) brain, the
absolute elevation in GroPSer levels (900 nmol/g increase)
is roughly ‘‘mass-balanced’’ by the reduction in corresponding
serine levels (650 nmol/g decrease), lending support to
a model where 40% of free serine is generated from GDE1-
catalyzed hydrolysis of GroPSer.
Serine exists in both L- and D-enantiomers in brain, and the
latter metabolite serves as a neurotransmitter that activates
NMDA receptors (Mothet et al., 2000; Snyder and Kim, 2000).
We therefore asked whether L- and D-serine were similarly
altered in GDE1(/) brains. To answer this question, we deriv-
atized both enantiomers of serine with the chiral coupling part-
ner N-(N-a-t-Boc-phenylalanyloxy)succinimide (BocPheOSu) toDE1
brain samples (C and D) were tested for activity against synthetic GroP metab-
ol (GroPIns). Enzyme activity was determined by quantification of the release of
oPIns, respectively) by LC-MS in recombinant GDE1 assays. For mouse brain
eway, and, forGroPIns,wasdeterminedbymeasuring reductions in consumed
tol in brain samples). All assays were performed with n = 3, **p < 0.01; *p < 0.05,
rabbit polyclonal antibodies raised against recombinant mouse GDE1 (D).
1–840, August 27, 2010 ª2010 Elsevier Ltd All rights reserved 835
Figure 4. GDE1 Regulates Free Serine Levels in Mouse Brain
(A) Levels of serine are reduced by 1.6-fold in GDE1(/) brains. Data represent the average of six independent experiments per group ±SE. *p < 0.05.
(B) Derivitization with BocPheOSu enables resolution of L- and D-serine via reverse-phase chromatography.
(C) BocPheOSu derivitization of brainmetabolomes reveals that both L- and D- serine levels are reduced by a similar magnitude in GDE1(/) brains. *p < 0.05 for
both enantiomers.
(D)Workingmodel for the role of GDE1 in serinemetabolism. Phosphatidylserine (PtdS) which is exclusively located on the inner leaflet of the plasmamembrane is
deacylated by A- or B-type phospholipases (PLA/B) whereupon the resulting GroPSer is released into the cytosol and is transported across the plasma
membrane by a putative GroPSer transporter. Subsequently, extracellular GroPSer is exposed to the catalytic domain of GDE1 resulting in the release of serine
and glycerol-3-phosphate. In the absence of GDE1, GroPSer accumulates, resulting in corresponding reductions in serine.
See also Figure S3.
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(Figure 4B). Derivatization of brain extracts with BocPheOSu
confirmed that both L- and D-serine are decreased by 1.6-fold
in GDE1(/) brains. Thus, GDE1(/) mice have constitutively
lower brain levels of the neuroactive substance D-serine.
DISCUSSION
GroP metabolites are thought to be formed by the action of
A/B-type phospholipases on membrane phospholipids, which
generate free fatty acids and water-soluble glycerol phospho-
diesters. It has been shown in yeast that deacylation of phospha-
tidylcholine (PtdC) by a B-type phospholipase (Nte1p, the ortho-
log of mammalian neuropathy target esterase) yields GroPCho,
which is catabolized by Gde1p (YPL110c) in a pathway that is
important for PtdC recycling (Dowd et al., 2001; Patton-Vogt,
2007). Less is known about the existence of other GroP metab-
olites or how they are enzymatically formed and degraded in
mammalian cells. This is an important problem not only from
the perspective of basic metabolism, but also signaling, since
GroPIns and its phosphorylated derivatives are dynamically836 Chemistry & Biology 17, 831–840, August 27, 2010 ª2010 Elseviregulated by various cell stimuli and have been shown to impact
processes such as cancer invasion and cytoskeletal remodeling
(for review, see Corda et al., 2009b). The development of robust
methods to measure GroP metabolites in complex biological
systems is critical to any effort aimed at characterizing mamma-
lian enzymes involved in GroP metabolism.
In this study, we established an LC-MS-based metabolomics
platform capable of detecting a wide range of aqueous-soluble,
polar analytes, including monosaccharides, nucleosides, amino
acids, and GroP metabolites. We used this platform to charac-
terize the polar metabolome of brains frommice lacking the glyc-
erophosphodiesterase GDE1. Previous studies have shown that
GDE1 acts as a GroPIns phosphodiesterase in vitro (Zheng et al.,
2003), and, accordingly, we observed dramatic (>20-fold) eleva-
tions in brain GroPIns from GDE1(/) mice. These findings
confirm that GroPIns is a physiological substrate for GDE1
in vivo.
Because ourmetabolomic profiling was performed in an untar-
geted manner, we also observed several other changes in the
polar metabolome. Most striking were two additional metabo-
lites that displayed large-magnitude elevations in GDE1(/)er Ltd All rights reserved
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metabolites by MS/MS fragmentation. Chemical synthesis and
comparison with standards revealed that these two substances
were GroP metabolites with serine and glycerate head-groups
(GroPSer and GroPGate, respectively). To our knowledge,
neither GroPSer nor GroPGate have been previously reported
as natural products in eukaryotes. This may be rationalized, at
least in part, by the low levels of GroPSer and GroPGate found
in GDE1(+/+) mice (<10 nmol/g brain tissue). These results thus
underscore one of the attributes of performing metabolomics
on enzyme-disrupted systems, which has the potential to
discover new metabolites that are too rare to detect in wild-type
models. In contrast, other GroP metabolites, including GroPEtn
and GroPCho, were not substantially altered in GDE1(/)
mice. These results indicate that GDE1 plays a broad, but not
exclusive role in regulating the ‘‘GroP metabolome,’’ which
appears to be much larger and more chemically diverse than
previously appreciated.
Beyond the GroP metabolome, we also observed a 40%
reduction in free serine in GDE1(/) brains. Quantitation of
the absolute magnitudes of serine reduction and GroPSer eleva-
tion indicate that these changes are mass-counterbalanced,
suggesting that GroPSer serves as a hitherto unappreciated
metabolic precursor to serine in the mammalian brain. The
biosynthesis and physiological role of serine in the nervous
system is a research topic of much interest. Serine is classified
as a nonessential amino acid because most eukaryotic cells
contain the enzymes necessary to biosynthesize it from 3-phos-
phoglycerate. In contrast, it was recently discovered that one of
these enzymes, 3-phosphoglycerate dehydrogenase (3PGDH),
is downregulated in neurons compared to astroglia, where it is
highly expressed (Yamasaki et al., 2001). Cerebellar Purkinje
neurons, in particular, lack detectable 3PGDH and therefore
cannot synthesize serine de novo (Furuya et al., 2000; Yamasaki
et al., 2001). These findings have led to a model wherein serine
is classified as a neurotrophic factor that is likely supplied by
proximal glia in vivo. Our data point to an important role for
GDE1 in maintaining the homeostatic balance of serine in the
nervous system. Intriguingly, GDE1 appears to be highly ex-
pressed in Purkinje neurons (Figure S3), suggesting that this
enzyme may provide certain neuronal populations with the
ability to scavenge serine from the interstitial space by catabo-
lizing GroPSer.
The biosynthesis of GroPSer itself is likely the result of
A/B-type phospholipase activity on membrane phospholipids.
As phosphatidylserine is localized exclusively on the inner-leaflet
of the plasma membrane (Martin et al., 1995), the resulting
GroPSer is presumably released into the cytosol whereupon it
must be transported outside the cell by transporters (Mariggio
et al., 2006; Patton-Vogt and Henry, 1998) prior to exposure to
GDE1, whose catalytic domain faces the luminal/extracellular
side of themembrane (Figure 4D) (Zheng et al., 2003). The result-
ing free serine generated by GDE1 may be taken up by neurons
and utilized directly, or taken up by glia for conversion to
D-serine by serine racemase (Mothet et al., 2000; Wolosker
et al., 1999; Yamamoto et al., 2003).
Serine is also of special relevance to the nervous system
because its D-enantiomer is an endogenous coagonist of brain
NMDA receptors (Mothet et al., 2000; Snyder and Kim, 2000).Chemistry & Biology 17, 83Interestingly, Ca2+-mediated release of D-serine from astrocytes
is required for NMDA receptor-mediated long-term potentiation
at nearby excitatory synapses (Henneberger et al., 2010). We
found that both L- and D-serine are reduced by approximately
40% in the brains ofGDE1(/) mice.While thesemice are overtly
normal, itmaybe interesting to look formorespecificdifferences in
nervous system function and behavior, as serine racemase(/)
mice, which lack D-serine, show elevated anxiety (Basu et al.,
2009) and are resistant to various forms of neurotoxicity (Inoue
et al., 2008). Additionally, several neurological disorders are
caused by extreme serine deficiency in humans owing in part to
loss of D-serine (de Koning and Klomp, 2004).
The biosynthetic origin(s) of GroPGate are more perplexing.
Whereas the deacylation of membrane phospholipids to form
GroP metabolites is a well-documented phenomenon (Emilsson
and Sundler, 1984; Murray and McMaster, 2005; Simon and
Cravatt, 2006), the existence of a suitable phospholipid
precursor for GroPGate via deacylation (e.g., phosphatidylgly-
cerate) has not been reported. As such, GroPGate may be
produced through another mechanism, possibly metabolic
conversion from GroPSer.
In conclusion, we have shown using an untargeted metabolo-
mics approach that GDE1 regulates several GroP metabolites
in the mammalian brain, including GroPIns, GroPSer, and
GroPGate. All three metabolites were subsequently verified to
be direct substrates of GDE1 in vitro. Because the catalytic
domain of GDE1 faces the extracellular side of the membrane
(Zheng et al., 2003), our findings indicate that these metabolites
likely transit through the interstitial space in the brain, raising
the intriguing possibility that they may serve as signaling mole-
cules in their own right, a possibility consistent with some of
the proposed functions of GroPIns and its phosphorylated
derivatives (Corda et al., 2009b). Further investigation of the
potential metabolic and signaling functions of GroP metabolites
will benefit from the availability of animal models, such as
GDE1(/) mice, that have substantial alterations in the GroP
metabolome.
SIGNIFICANCE
Glycerophosphodiesterases (GDEs) catalyze the hydrolysis
of the phosphodiester bond in glycerophospho (GroP)
metabolites. Numerous GDE enzymes have been character-
ized in prokaryotes, but it is only recently that we have begun
to appreciate the roles played by these enzymes in
mammals. Here, we have characterized the polar metabo-
lome of mice bearing a targeted disruption in the GDE1
gene. This represents the first unbiased attempt to identify
thephysiological substrates of aGDEenzyme in a eukaryotic
organism. By applying an untargeted LC-MS-basedmetabo-
lomic profiling technique, we found that GroP-inositol (Gro-
PIns), a known in vitro substrate for GDE1, is dramatically
elevated in the central nervous system of GDE1(/) mice,
as were two other metabolites. Analytical and synthetic
chemistry methods were used to elucidate the structures
of these metabolites as GroP-serine (GroPSer) and GroP-
glycerate (GroPGate), neither of which, to our knowledge,
have been previously described as natural products in
eukaryotes. All three GroP metabolites were confirmed to1–840, August 27, 2010 ª2010 Elsevier Ltd All rights reserved 837
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profiles also revealed a 40% reduction in free serine levels
in the brain of GDE1(/) mice. Interestingly, this reduction
was similar in magnitude to the corresponding elevation in
GroPSer in these animals, indicating that GroPSermay serve
as a metabolic reservoir for serine in the central nervous
system. Subsequent derivitization studies demonstrated
that this 40% reduction was observed for both L- and D-
serine, a significant result given that the latter amino acid
is a neurotransmitter involved in long-term potentiation
and neuroprotection. Taken together, these findings indi-
cate that the mammalian ‘‘GroP metabolome’’ is quite
diverse in structure and function and designate GDE1 as
one of its principal enzymatic regulators in vivo.
EXPERIMENTAL PROCEDURES
Metabolome Preparation
For the isolation of water-soluble metabolites a methanol-water extraction
protocol was used, essentially as previously described (Rabinowitz and
Kimball, 2007). In brief, male GDE1(+/+) and (/) mice (8–12 weeks old)
were sacrificed and tissue was isolated and flash frozen in liquid nitrogen.
Frozen brains were weighed and placed into a dounce tissue homogenizer
with 1.5 ml ice-cold 80:20 CH3OH:water and homogenized with 10 strokes
of the pestle. Each sample was sonicated and centrifuged at 10,000 3 g to
separate insoluble material. The resulting pellet was re-extracted with 500 ml
of 80:20 CH3OH:water and centrifuged once again. The combined supernatant
was dried down with a SpeedVac at 37C, resuspended in 50 ml of water, and
stored at 80C or injected directly into the mass spectrometer.
LC-MS
Tissuemetabolome samples were analyzed using an Agilent 1100 LC-MSD SL
instrument with ionization achieved via electrospray ionization (ESI). The scan
range was set to 100–1200 Da with a source voltage of 3.0 kV. The fragmentor
voltage was set to 100 V, the drying gas flow rate was 10 liters/min, and the
nebulizer pressure was 35 psi. Normal-phase chromatography was performed
with a Luna-5 mm NH2 column (50 3 4.60 mm, Phenomenex, Torrance, CA).
Mobile phases were as follows, Buffer A: MeCN, Buffer B: 95:5 H2O:CH3CN
with 50 mM NH4OAc and 0.2% NH4OAc with a resulting pH of 9.3. A 30 min
gradient was applied: 0–100% buffer B followed by 10 min of isocratic flow
with 100% buffer B. The flow rate was 0.5 ml/min. For each run the injection
volume was 10 ml.
The obtained data were exported as common data format (.CDF) files.
Differentially abundant metabolites between sample pairs were identified
with the XCMS analyte profiling software, which aligns and quantifies the rela-
tive signal intensities of mass peaks from multiple LC-MS traces (Smith et al.,
2006). Significant peak changes between samples were confirmed by manual
quantification by calculating the area under the peak from raw chromato-
grams. For some experiments an internal d3-serine standard (85 nmol) was
added to the extraction solution. Absolute GroP levels were estimated by
comparison to external calibration curves with synthetic GroP metabolites
and d3-serine.
Tandem MS and High Mass-Accuracy Measurements
Initial mass-measurements andMS/MS experiments were performed using an
Agilent 6520 Accurate Mass QTOF instrument coupled to an Agilent 1100 LC
system. Samples were chromatographed as described above and analyzed in
negative ionization mode. The source temperature was set to 350C with
a cone gas flow of 11 liters/hr, a desolvation gas temperature of 300C, and
a nebulization pressure of 45 psig. The capillary voltage was set at 4 kV,
the fragmentor voltage to 100 V and the skimmer voltage to 64 V. The collision
energy was set at 35 V. Data were collected using a mass range of 100–1200
Da with an acquisition time of 1.0 s per spectrum. For MS/MS data, GroPIns
(333.0), GroPSer (258.0), and GroPGate (259.0) ions were targeted for
fragmentation.838 Chemistry & Biology 17, 831–840, August 27, 2010 ª2010 ElseviHigh mass-accuracy measurements (Table S4) were obtained via Fourier
transform ion cyclotron resonance (FT-ICR) mass spectrometry using an
Apex II 7.0T FT-ICR mass spectrometer (Bruker Daltonics, Billerica, MA)
coupled to an Agilent 1100 LC. This system is equipped with a custom electro-
spray sourcewith two nebulizers for dual spray ionization enabling operation in
‘‘lock-mass’’ mode via the constant infusion of three compounds (omeprazole
at 344.1074 m/z, hymecromone sulfate at 254.9969, and indoxyl sulfate at
212.0023) for internal calibration. A 1 megaword file size was used resulting
in an acquisition time of 0.9 s per spectrum. Using these parameters,
247,000 resolving power was achieved at 259 m/z.
Preparation and Purification of GroPIns, GroPSer, and GroPEtn
To obtain GroPIns, GroPSer, and GroPEtn, commercially available phosphati-
dylinositol, phosphatidylserine, and phosphatidylethanolamine were hydro-
lyzed according to the following procedure. In a 4 ml glass vial provided with
a magnetic stirring bar 25 mg phospholipid was dissolved in 3 ml 2:1
CHCl3:CH3OH. 1 ml 2 N NaOH was added and the mixture was stirred at
room temperature. The progress of the reaction was checked by TLC (devel-
oped with 80:20 CH2Cl2:CH3OH) and, after complete hydrolysis was observed
(usually after 1–2 hr), the reaction was neutralized by the addition of 1 ml 2 N
HCl. To separate the desired GroP products from the liberated free fatty acids
the reaction mixture was extracted twice with 2 ml of water. The combined
aqueous phases were washed with 2 ml CHCl3, frozen in liquid nitrogen, and
lyophilized over night.
To separate the crude product from small molecules by-products and inor-
ganic salts gel filtration chromatography was performed by dissolving the lyo-
philate in a minimum amount of water and passing it over a column packed
with Sephadex LH-20 material (Sigma Aldrich) using 80:20 MeOH:water as
mobile phase to obtain the desired products.
GroPSer: 1H-NMR (300 MHz, D2O): d 3.6–3.8 (m, 2H); 3.87 (m, 1H);
3.95 (m, 3H); 4.0–4.2 (m, 2H). ESI-MS calculated for C6H13NO8P
-:
258.03843, found 258.03861.
GroPEtn: 1H-NMR (300 MHz, D2O): d 3.25 (t, 2H, J = 5.4 Hz), 3.5–3.7
(m, 2H), 3.8–4.0 (m, 5H). ESI-MS calculated for C5H13NO6P
-:
214.04860, found 214.04702.Chemical Synthesis of bis([2,2-Dimethyl-1,3,-Dioxolan-4-yl]Methyl)
Phenyl Phosphate
To a solution of phenyl dichlorophosphate (600 ml, 4.0 mmol) in 20 ml dichloro-
methane and DIEA (4 ml) at 0C, solketal (930 ml, 7.5 mmol) was added drop-
wise and the reaction was stirred at room temperature for 3 hr. Phosphate
buffer (pH 7) was added to a reaction, and the reaction was stirred for
additional 1 hr to hydrolyze extra phenyl dichlorophosphate. After an addition
of dichloromethane, organic layer was collected, and further washed with
phosphate buffer (pH 7) three times to give bis((2,2-dimethyl-1,3,-dioxolan-
4-yl)methyl) phenyl phosphate (935 mg, 62%).
1H-NMR (300MHz, CDCl3): d 1.36 (s, 6H), 1.45 (s, 3H), 1.47 (s, 3H), 3.87
(m, 2H), 4.10 (m, 2H), 4.2–4.3 (m, 4H), 4.40 (m, 2H), 7.2–7.3 (m, 2H),
7.38 (m, 3H). ESI-MS (ESI+): m/z 403 (M + H)+.Chemical Synthesis of GroPGate
To a solution of glycerophosphoserine (GroPSer) (26 mg, 100 mmol) in 0.5 N
HCl (2 ml) was added NaNO2 (15 mg, 220 mmol) at 4
C with stirring. After
12 hr, 100 ml NaOH were added and the reaction mixture was flash frozen
with liquid nitrogen and lyophilized over night. The resulting white solid was
dissolved in a minimum amount of water and purified using Sephadex LH-20
gel filtration material as described above affording GroPGate as a white solid.
1H-NMR (300MHz, D2O): d 3.7–3.9 (m, 2H); 3.98 (m, 1H); 4.05 (m, 2H); 4.20 (m,
1H); 4.33 (m, 2H). ESI-MS calculated for C6H12O9P
-: 259.02244, found
259.02241.
Analysis of D- and L-Serine Levels in Brain Tissue
To effect the transformation of the serine enantiomers into diastereomers by
derivatization with N-(N-a-t-Boc-phenylalanyloxy)succinimide (BocPheOSu)
D-serine, L-serine or a mixture thereof (104 mg, 1 mmol) was dissolved iner Ltd All rights reserved
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Novel Substrates for GDE1 Revealed by Metabolomics500 ml PBS and BocPheOSu (10mg, 25 mmol) was added. After stirring at room
temperature for 3 hr the reaction mixture was directly analyzed by LC-MS on
an Agilent Eclipse XDB-C18 column (5 mM, 4.6 mm 3 150 mm). Mobile phase
A consisted of 95:5 water and methanol, with 0.1% of 28% ammonium
hydroxide, and mobile phase B consisted of 60:55:5 2-propanol, CH3OH,
and water, with 0.1% of 28% ammonium hydroxide. The gradient started at
5% B and then linearly increased to 45% B over 40 min followed by 100% B
for 10 min at a flow rate of 0.5 ml/min. In this way the retention times of Boc-
PheOSu-derivatized D- and L-serine were determined. For serine level anal-
ysis in brains, tissue samples were prepared and metabolites were extracted
as described above. The resuspended metabolome (10 ml of the 50 ml resus-
pension) was derivatizedwith BocPheOSu following the derivatizedmetabolite
mixture was analyzed by reverse-phase LC-MS as described above.Enzyme Assays
Enzyme assays were performed with LC-MS by observing the formation of
serine and glycerate in the cases of GroPSer and GroPGate, and by observing
formation of inositol (for recombinant GDE1 assays) or reduction of substrate
(for mouse brain samples) in the case of GroPIns. For recombinant GDE1
assays an N-terminal Myc-fusion of GDE1 was transiently overexpressed in
COS-7 cells and membrane fractions prepared as described previously
(Simon and Cravatt, 2008). The membrane samples were resuspended in
assay buffer (50 mM Tris, 2 mM MgCl2 [pH 8.0]). Assays were carried out in
100 ml total reaction volume. For each reaction 200 mM of substrate was incu-
bated with a final concentration of 0.1 mg/ml cell-lysate or 0.5 mg/ml mouse
brain membrane preparation respectively. Reactions were incubated at
37C for 3 hr (in the case of GroPSer and GroPGate) or 9 hr (in the case of
GroPIns) before quenching with 1.0 ml CH3OH. Subsequently, 25 nmol of
D3-serine were added to each reaction as an internal standard. Samples
were centrifuged at 1400 3 g for 3 min, and dried down under vacuum. For
normal phase LC-MS analysis samples were resuspended in 30 ml water and
injected into an Agilent 1100 LC-MSD SL instrument applying the following
gradient: 15%–90% buffer B over 15 min followed by isocratic flow with
100%B for 5 min at a flow rate of 0.5 ml/min. For each run the injection volume
was 30 ml. Each assay was conducted with an n = 3.SUPPLEMENTAL INFORMATION
Supplemental Information includes three figures and four tables and can be
found with this article online at doi:10.1016/j.chembiol.2010.06.009.ACKNOWLEDGMENTS
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